Question:

A novel targeted therapy for prostate cancer is approved for use but faces challenges in terms of cost and availability. What is the most effective strategy to address these barriers and ensure equitable access to the treatment?

Answer: How did you do?? Click here to find out or post your answer below!

1 - Increase the price of the drug to ensure profitability.

2 - Limit the use of the drug to patients with specific genetic profiles.

3 - Develop patient assistance programs to support treatment costs.

4 - Prioritize access to the drug for patients in academic centers.

5 - Discontinue the use of the drug due to accessibility challenges.

Can you answer the questions about this case? Watch Prof Gain's session, who chairs a discussion on this topic in our Advanced Prostate Cancer Course

Mr. Taylor is a 79-year-old retired chef with a history of chronic kidney disease, congestive heart failure, and COPD. He recently presented to his primary care physician with new-onset back pain and urinary difficulties. Examination revealed mid-back tenderness and a diffusely enlarged prostate. His PSA level was markedly elevated at 65.4 ng/mL.

This program is funded by an independent grant from Merck. This online education program has been designed solely for healthcare professionals in USA. The content is not available for healthcare professionals in any other region.

Can you answer the questions about this case? Watch Prof Gain's session, who chairs a discussion on this topic in our Advanced Prostate Cancer Course

Mr. Smith, a 65-year-old retired teacher in good overall health, presented for his annual checkup. His routine blood work revealed an increasing trend in his prostate-specific antigen (PSA) levels over the past two years. After experiencing increased urinary frequency and nocturia, he was referred to a urologist. An MRI revealed a lesion in the left posterior peripheral zone of the prostate with suspected extraprostatic extension. A subsequent MRI fusion biopsy confirmed high-risk prostate cancer (Grade Group 4). A PSMA-PET scan further revealed an avid lymph node and sclerotic bone metastasis, indicating early (oligo) metastatic disease.

This program is funded by an independent grant from Merck. This online education program has been designed solely for healthcare professionals in USA. The content is not available for healthcare professionals in any other region.